Get started
Author

Charlotte Wood

Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
2022 · David T. Teachey, Meenakshi Devidas, et al. · Journal of Clinical Oncology · 158
Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4
2014 · Anne L. Angiolillo, Reuven J. Schore, et al. · Journal of Clinical Oncology · 135
PDF
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group
2011 · Martin A. Champagne, Cecilia H. Fu, et al. · Pediatric Blood & Cancer · 58
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
2024 · Robert J. Hayashi, Michelle L. Hermiston, et al. · Blood · 18
Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231
2020 · David T. Teachey, Meenakshi Devidas, et al. · Blood · 10
Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group
2022 · Caitlin W. Elgarten, Joel C. Thompson, et al. · Pediatric Blood & Cancer · 5
Imatinib in Children with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP CML): AAML0123 COG Study.
2006 · Martin A. Champagne, Cecilia Fu, et al. · Blood · 3
Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231
2022 · Robert J. Hayashi, Michelle L. Hermiston, et al. · Blood · 1
Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation
2021 · Paul Harker-Murray, Brent L. Wood, et al. · Blood · 1
Comparison of chemotherapy dose intensity for AYAs on COG AALL1131 versus CALGB 10403.
2020 · Jennifer Lynn McNeer, Lingyun Ji, et al. · Journal of Clinical Oncology · 1
Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG e. coli L-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4.
2012 · Anne L. Angiolillo, Reuven J. Schore, et al. · Journal of Clinical Oncology · 1
Works count: 11
Citation count: 391
H-index: 5
I10-index: 5
Year
Topic
Type